Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies.
Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Roeker LE, et al. Among authors: abhyankar s. Acta Haematol. 2024 Jun 1. doi: 10.1159/000539587. Online ahead of print. Acta Haematol. 2024. PMID: 38824917
Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation.
Shahzad M, Amin MK, Bellman P, Al-Ramahi J, Noor J, Vyas A, Mahmoudjafari Z, McGuirk M, DeJarnette S, Ahmed N, Abdallah AO, Shune L, Singh AK, McGuirk JP, Abhyankar S, Mushtaq MU. Shahzad M, et al. Among authors: abhyankar s. Transfusion. 2024 Jun 7. doi: 10.1111/trf.17909. Online ahead of print. Transfusion. 2024. PMID: 38847196
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
Shahzad M, Khalid MF, Amin MK, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SG, Ahmed N, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: abhyankar sh. Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):88-94. doi: 10.56875/2589-0646.1118. Hematol Oncol Stem Cell Ther. 2024. PMID: 38560970
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. McGuirk M, et al. Among authors: abhyankar sh. Transpl Immunol. 2024 Jun;84:102039. doi: 10.1016/j.trim.2024.102039. Epub 2024 Mar 19. Transpl Immunol. 2024. PMID: 38513813 Free article.
Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation.
Al-Ramahi JS, Shahzad M, Nguyen A, Li K, Amin MK, Ahmed N, Lutfi F, DeJarnette S, Chaudhary SG, Bansal R, Abdelhakim H, Shune L, Abdallah AO, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Al-Ramahi JS, et al. Among authors: abhyankar sh. Bone Marrow Transplant. 2024 Jan;59(1):134-137. doi: 10.1038/s41409-023-02125-x. Epub 2023 Oct 13. Bone Marrow Transplant. 2024. PMID: 37833526 No abstract available.
"Waitlist mortality" is high for myeloma patients with limited access to BCMA therapy.
Ahmed N, Wesson W, Mushtaq MU, Bansal R, AbdelHakim H, Bromert S, Appenfeller A, Ghazal BA, Singh A, Abhyankar S, Ganguly S, McGuirk J, Abdallah AO, Shune L. Ahmed N, et al. Among authors: abhyankar s. Front Oncol. 2023 Aug 3;13:1206715. doi: 10.3389/fonc.2023.1206715. eCollection 2023. Front Oncol. 2023. PMID: 37601685 Free PMC article.
213 results